Loxo Oncology, Inc. (LOXO) Director Sells $450,000.00 in Stock
Loxo Oncology, Inc. (NASDAQ:LOXO) Director Avi Z. Naider sold 5,000 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $90.00, for a total transaction of $450,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Loxo Oncology, Inc. (NASDAQ:LOXO) traded up 0.35% on Wednesday, reaching $88.56. 503,016 shares of the company’s stock traded hands. Loxo Oncology, Inc. has a 52 week low of $17.14 and a 52 week high of $95.92. The firm’s market capitalization is $2.64 billion. The company has a 50 day moving average price of $85.53 and a 200 day moving average price of $67.91.
Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by ($0.15). During the same quarter in the previous year, the business earned ($0.77) EPS. On average, equities research analysts predict that Loxo Oncology, Inc. will post ($4.49) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Loxo Oncology, Inc. (LOXO) Director Sells $450,000.00 in Stock” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/18/loxo-oncology-inc-loxo-director-sells-450000-00-in-stock.html.
Several brokerages have weighed in on LOXO. BidaskClub lowered shares of Loxo Oncology from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. BTIG Research restated a “buy” rating and set a $75.00 target price on shares of Loxo Oncology in a research report on Thursday, August 3rd. Zacks Investment Research lowered shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. Stifel Nicolaus restated a “buy” rating and set a $94.00 target price (up from $71.00) on shares of Loxo Oncology in a research report on Thursday, August 10th. Finally, JMP Securities lowered shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $83.12 to $17.14 in a research report on Tuesday, August 29th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Loxo Oncology has an average rating of “Buy” and an average target price of $76.31.
A number of institutional investors have recently added to or reduced their stakes in LOXO. FMR LLC increased its stake in Loxo Oncology by 20.6% during the 1st quarter. FMR LLC now owns 3,922,013 shares of the biopharmaceutical company’s stock valued at $165,039,000 after buying an additional 670,306 shares during the period. Lord Abbett & CO. LLC increased its stake in Loxo Oncology by 372.0% during the 2nd quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock valued at $59,304,000 after buying an additional 582,862 shares during the period. Marshall Wace North America L.P. acquired a new position in Loxo Oncology during the 2nd quarter valued at about $33,347,000. State Street Corp increased its stake in Loxo Oncology by 155.2% during the 1st quarter. State Street Corp now owns 547,017 shares of the biopharmaceutical company’s stock valued at $23,019,000 after buying an additional 332,696 shares during the period. Finally, Alliancebernstein L.P. increased its stake in Loxo Oncology by 50.2% during the 2nd quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock valued at $75,121,000 after buying an additional 312,988 shares during the period.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.